Revance Reports Third Quarter 2021 Financial Results, Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Revance Therapeutic (RVNC) PT Lowered to $31 at Stifel
November 10, 2021 6:49 AM ESTStifel analyst Annabel Samimy lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $31.00 (from $33.00) while maintaining a Buy rating.
The analyst commented, "RVNC reported solid revenues ($19.8mn/ Cons $20.3) from steady RHA-filler sales ($18.3mn) in a seasonally difficult quarter and meaningful expansion of... More
Revance Therapeutics (RVNC) Tops Q3 EPS by 5c
November 9, 2021 4:55 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($1.10), $0.05 better than the analyst estimate of ($1.15). Revenue for the quarter came in at $19.7 million versus the consensus estimate of $20.29 million.
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.
... More